Perspective Therapeutics Statistics
Share Statistics
Perspective Therapeutics has 67.59M shares outstanding. The number of shares has increased by -75.97% in one year.
| Shares Outstanding | 67.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.92M |
| Failed to Deliver (FTD) Shares | 349.48K |
| FTD / Avg. Volume | 22.68% |
Short Selling Information
The latest short interest is 8.02M, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 8.02M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 16.38% |
| Short Ratio (days to cover) | 9.06 |
Valuation Ratios
The PE ratio is -2.31 and the forward PE ratio is -9.88.
| PE Ratio | -2.31 |
| Forward PE | -9.88 |
| PS Ratio | 75.03 |
| Forward PS | null |
| PB Ratio | 1.43 |
| P/FCF Ratio | -2.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Perspective Therapeutics Inc. has an Enterprise Value (EV) of 14.53M.
| EV / Earnings | -0.31 |
| EV / Sales | 10.13 |
| EV / EBITDA | -0.36 |
| EV / EBIT | -0.35 |
| EV / FCF | -0.38 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.07 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.24 |
| Cash Flow / Debt | -21.4 |
| Interest Coverage | -487.39 |
Financial Efficiency
Return on equity (ROE) is -0.62% and return on capital (ROIC) is -49.19%.
| Return on Equity (ROE) | -0.62% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -49.19% |
| Revenue Per Employee | 12.36K |
| Profits Per Employee | -400.93K |
| Employee Count | 116 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.65M |
| Effective Tax Rate | 0.07 |
Stock Price Statistics
The stock price has increased by 28.73% in the last 52 weeks. The beta is 1.47, so Perspective Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | 28.73% |
| 50-Day Moving Average | 9.18 |
| 200-Day Moving Average | 12.41 |
| Relative Strength Index (RSI) | 22.27 |
| Average Volume (20 Days) | 1.54M |
Income Statement
In the last 12 months, Perspective Therapeutics had revenue of $1.43M and earned -$46.51M in profits. Earnings per share was $-1.4.
| Revenue | 1.43M |
| Gross Profit | 1.43M |
| Operating Income | -40.94M |
| Net Income | -46.51M |
| EBITDA | -39.96M |
| EBIT | -40.94M |
| Earnings Per Share (EPS) | -1.4 |
Balance Sheet
The company has $9.24M in cash and $2.55M in debt, giving a net cash position of $6.69M.
| Cash & Cash Equivalents | 9.24M |
| Total Debt | 2.55M |
| Net Cash | 6.69M |
| Retained Earnings | -152.44M |
| Total Assets | 391.15M |
| Working Capital | 242.03M |
Cash Flow
In the last 12 months, operating cash flow was -$36.91M and capital expenditures -$1.07M, giving a free cash flow of -$37.98M.
| Operating Cash Flow | -36.91M |
| Capital Expenditures | -1.07M |
| Free Cash Flow | -37.98M |
| FCF Per Share | -1.42 |
Margins
Gross margin is 100%, with operating and profit margins of -2.86K% and -3.24K%.
| Gross Margin | 100% |
| Operating Margin | -2.86K% |
| Pretax Margin | -2.80K% |
| Profit Margin | -3.24K% |
| EBITDA Margin | -2.79K% |
| EBIT Margin | -2.86K% |
| FCF Margin | -2.65K% |
Dividends & Yields
CATX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -40.58% |
| FCF Yield | -16.29% |
Analyst Forecast
The average price target for CATX is $20, which is 479.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 479.7% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Jun 17, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 1.89 |
| Piotroski F-Score | 4 |